Comment on “Topically Applied Connective Tissue Growth Factor/CCN2 Improves Diabetic Preclinical Cutaneous Wound Healing: Potential Role for CTGF in Human Diabetic Foot Ulcer Healing”

Figure 1

Procedures of creating wounds and securing silicone splints and “Tegaderm”: (a) glue the silicone splint to the “Tegaderm” inner surface; (b) clip the silicone splint with the “Tegaderm” layer together; (c) treat the rat with conventional anesthetization, skin preparation and sterilization, then put it in ventral recumbency; (d) measure and locate the wounds with the shaped rubber stamp inked with gentian violet; (e) create four full-thickness wounds on the rat dorsum; (f) gross appearance of single wound; (g) suture the silicone splint with “Tegaderm” together; (h) gross appearance of single wound covered with silicone splint and “Tegaderm” sutured together.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)